🧬 Genetic Disorder

Carney Complex

Also known as: CNC, LAMB syndrome, NAME syndrome

Carney complex (CNC) is a rare, autosomal dominant multiple neoplasia syndrome characterized by spotty skin pigmentation (lentigines, blue nevi, and café-au-lait spots), myxomas (cardiac, cutaneous, and mammary), endocrine tumors (primary pigmented nodular adrenocortical disease leading to Cushing syndrome, thyroid tumors, and testicular tumors), and schwannomas. Other manifestations can include large cell calcifying Sertoli cell tumors (LCCSCTs) of the testes, ductal adenomas of the breast, psammomatous melanotic schwannomas (PMS), and growth hormone-producing pituitary adenomas (acromegaly).

ICD-10: Q87.8 Orphanet: 148 OMIM: 160980
👥 <1 / 1 000 000 Prevalence
🔬 15 Active Trials

Carney Complex is like having spots on your skin and sometimes getting bumps (tumors) in your heart, skin, or other places. Doctors need to check you regularly to make sure the bumps don't cause problems.

Signs & Symptoms

  • Spotty skin pigmentation (lentigines, blue nevi, café-au-lait spots)
  • Cardiac myxomas
  • Cutaneous myxomas
  • Mammary myxomas
  • Primary pigmented nodular adrenocortical disease (PPNAD) causing Cushing syndrome
  • Thyroid tumors
  • Testicular tumors (large cell calcifying Sertoli cell tumors)
  • Growth hormone-producing pituitary adenomas (acromegaly)
  • Psammomatous melanotic schwannomas

Treatment Options

SURGERY

Surgical resection of cardiac myxomas

HIGHLY EFFECTIVE
SURGERY

Surgical resection of cutaneous myxomas

HIGHLY EFFECTIVE
SURGERY

Adrenalectomy for PPNAD

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Somatostatin analogs (e.g., octreotide, lanreotide) for acromegaly

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Dopamine agonists (e.g., cabergoline) for acromegaly

MODERATELY EFFECTIVE
SURGERY

Pituitary surgery for acromegaly

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Mitotane for PPNAD (off-label)

MODERATELY EFFECTIVE
SURGERY

Thyroidectomy for thyroid tumors

HIGHLY EFFECTIVE
SUPPORTIVE

Surveillance and monitoring for tumor recurrence

SUPPORTIVE

Diagnosis

  • Clinical examination
  • Skin biopsy
  • Echocardiography
  • MRI of the heart, brain, and pituitary
  • Endocrine testing (cortisol, growth hormone, IGF-1)
  • Genetic testing for PRKAR1A mutations
  • Histopathological examination of tumors

History

Carney complex was first described by J. Aidan Carney in 1985, who recognized the association of cardiac myxomas, skin pigmentation, and endocrine overactivity. The genetic basis of the disease was later identified as mutations in the PRKAR1A gene.

Recent Breakthroughs

2022

Novel PRKAR1A mutations identified in Carney Complex patients

Researchers identified several novel PRKAR1A mutations in patients with Carney Complex, expanding the spectrum of known mutations and improving diagnostic capabilities.

2023

Improved imaging techniques for early detection of cardiac myxomas

Advancements in cardiac MRI technology have improved the early detection of small cardiac myxomas in Carney Complex patients, allowing for timely intervention.